Stockscreener 앱 받기
25.15
2.99%
0.73
시간 외 거래:
25.19
0.04
+0.16%
전일 마감가:
$24.42
열려 있는:
$24.55
하루 거래량:
4.90M
Relative Volume:
1.83
시가총액:
$19.50B
수익:
$220.00K
순이익/손실:
$-1.08B
주가수익비율:
-17.41
EPS:
-1.4448
순현금흐름:
$-326.53M
1주 성능:
+27.86%
1개월 성능:
+58.68%
6개월 성능:
+19.82%
1년 성능:
+2.19%
1일 변동 폭
$24.06
$25.48
1주일 범위
$19.52
$25.48
52주 변동 폭
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
25.15 | 18.93B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 110.81B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 78.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 42.71B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-08 | 개시 | Stifel | Buy |
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Board seats, pay and equity plan on ballot at Summit Therapeutics (NASDAQ: SMMT) - Stock Titan
UBS reiterates Buy on Summit Therapeutics stock ahead of trial data - Investing.com Canada
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Summit Therapeutics Inc Stock (SMMT) Moved Up by 12.03% on Apr 16: Drivers Behind the Movement - TradingKey
Wall Street Hits New Records, Oil Surges On Hormuz Toll Drama: What's Moving Markets Thursday? - Benzinga
Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.2%Still a Buy? - MarketBeat
SMMT Stock Up 24% in Three Months: Here's What You Need to Know - Yahoo Finance
Been holding for so long - Moomoo
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic - MSN
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing - Stock Traders Daily
Summit Therapeutics has scarcity value in a crowded drug race: Analyst - MSN
What makes Summit Therapeutics (SMMT) one of the best large caps under $30 - MSN
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - ADVFN
Aug PostEarnings: Can Summit Therapeutics Inc be the next market leader2026 Investor Takeaways & Growth Focused Entry Point Reports - baoquankhu1.vn
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Inflation Data: Can Summit Therapeutics Inc stock outperform in a bear marketBreakout Watch & Stock Portfolio Risk Control - baoquankhu1.vn
SMMT Analyst Rating: Citigroup Initiates Buy Coverage April 2026 - Meyka
Stifel initiates coverage of Summit Therapeutics (SMMT) with buy recommendation - MSN
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst - Sahm
SMMT Upgraded to Buy by Citigroup on April 08, 2026 - Meyka
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
SMMT : POTENTIAL BOUNCEBACK Click Through The Up Coming Page (2dUA4zfHbg) - Mshale
SUMMIT THERAPEUTICS INC BIG TRADING SWING | SMMT STOCK Simply Click The Next Internet Page (JHLdCFn8fQ) - Mshale
Citigroup starts coverage of Summit Therapeutics Inc (SMMT), Apr 08 2026, Buy - Meyka
What's Going On With Summit Therapeutics Stock Wednesday?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
$Summit Therapeutics (SMMT.US)$ - Moomoo
Stifel Initiates Coverage on Summit Therapeutics (SMMT) with 'Bu - GuruFocus
Pullback Watch: Is Summit Therapeutics Inc forming higher highs and higher lowsQuarterly Portfolio Review & Low Drawdown Investment Ideas - baoquankhu1.vn
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
Tudor Investment Corp ET AL Takes $7.17 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Stifel Initiates Coverage on Summit Therapeutics (SMMT) with 'Buy' Rating | SMMT Stock News - GuruFocus
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Aug Selloffs: Is Summit Therapeutics Inc impacted by rising ratesQuarterly Market Review & High Accuracy Swing Trade Signals - baoquankhu1.vn
Stifel Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $45 - Moomoo
Sentiment Recap: Does Summit Therapeutics Inc have a sustainable dividendInsider Buying & Expert Curated Trade Ideas - baoquankhu1.vn
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - MSN
Aberdeen Group plc Reduces Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (SMMT) asks shareholders to approve 8M-share Plan increase - Stock Titan
Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - MSN
Chart Watch: Whats next for Summit Therapeutics Inc stockEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn
We're Not Very Worried About Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Rate - Moomoo
Does Summit Therapeutics (SMMT) Expanding Ivonescimab Trials Clarify Its Single-Asset Oncology Strategy? - simplywall.st
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - AOL.com
(SMMT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Summit plunges 80 percent after muscle-wasting disorder drug fails - AOL.com
SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Assenagon Asset Management S.A. Invests $1.04 Million in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
2.19%
0.43%
자본화:
|
볼륨(24시간):